Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InnoCare Pharma Ltd. ( (HK:9969) ) just unveiled an update.
InnoCare Pharma Ltd. reported a significant increase in revenue for the first half of 2025, with a 74.3% rise to RMB731.4 million compared to the same period in 2024. This growth was primarily driven by the strong sales performance of Orelabrutinib and licensing revenue from Prolium. Despite the increase in revenue, the company reported a loss of RMB35.6 million, although this was a substantial improvement from the previous year’s loss of RMB267.9 million. The financial results highlight the company’s expanding market presence and the growing acceptance of its products, particularly Orelabrutinib, which saw a 52.8% increase in sales due to expanded coverage and a higher number of patients treated.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$25.20 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company focused on developing and commercializing innovative therapies for cancer and autoimmune diseases. The company is known for its product Orelabrutinib, which is a key driver of its sales growth.
Average Trading Volume: 19,266,452
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.33B
For an in-depth examination of 9969 stock, go to TipRanks’ Overview page.